Background Rifaximin is a non-absorbable antibiotic used to prevent relapses of hepatic encephalopathy which may also be a candidate for prophylaxis of spontaneous bacterial peritonitis (SBP). Aim To detect the impact of rifaximin on the occurrence and characteristics of SBP. Methods We prospectively studied all hospitalized patients that underwent a diagnostic paracentesis in our department from March 2012 to April 2013 for SBP and recorded all clinical data including type of SBP prophylaxis, prior use of rifaximin, concomitant complications of cirrhosis, as well as laboratory results and bacteriological findings. Patients were divided into the following three groups: no antibiotic prophylaxis, prophylaxis with rifaximin or with systemically absorbed antibiotic prophylaxis. Results Our study cohort comprised 152 patients with advanced liver cirrhosis, 32 of whom developed SBP during the study period. As expected, our study groups differed regarding a history of hepatic encephalopathy and SBP before inclusion into the study. None of the 17 patients on systemic antibiotic prophylaxis developed SBP while 8/27 patients on rifaximin and 24/108 without prophylaxis had SBP (p = 0.02 and p = 0.04 versus systemic antibiotics, respectively). In general, episodes of SBP were similar for patients treated with rifaximin and those without any prophylaxis. However, Escherichia coli and enterococci were dominant in the ascites of patients without any prophylaxis, while mostly klebsiella species were recovered from the ascites samples in the rifaximin group. Conclusion Rifaximin pretreatment did not lead to a reduction of SBP occurrence in hospitalized patients with advanced liver disease. However, the bacterial species causing SBP were changed by rifaximin.
References
[1]
Wiest R, Krag A, Gerbes A (2012) Spontaneous bacterial peritonitis: recent guidelines and beyond. Gut 61: 297–310. doi: 10.1136/gutjnl-2011-300779
[2]
Thuluvath PJ, Morss S, Thompson R (2001) Spontaneous bacterial peritonitis—in-hospital mortality, predictors of survival, and health care costs from 1988 to 1998. Am J Gastroenterol 96: 1232–6.
[3]
Garcia-Tsao G (2001) Current management of the complications of cirrhosis and portal hypertension: variceal hemorrhage, ascites, and spontaneous bacterial peritonitis. Gastroenterology 120: 726–48. doi: 10.1053/gast.2001.22580
[4]
Ginès P, Rimola A, Planas R, Vargas V, Marco F, et al. (1990) Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial. Hepatology 12: 716–24. doi: 10.1002/hep.1840120416
[5]
Coltart I, Tranah TH, Shawcross DL (2013) Inflammation and hepatic encephalopathy. Arch Biochem Biophys 536: 189–96. doi: 10.1016/j.abb.2013.03.016
[6]
H？ussinger D, Schliess F (2008) Pathogenetic mechanisms of hepatic encephalopathy. Gut 57: 1156–65. doi: 10.1136/gut.2007.122176
[7]
Bass NM, Mullen KD, Sanyal A, Poordad F, Neff G, et al. (2010) Rifaximin treatment in hepatic encephalopathy. N Engl J Med 362: 1071–81. doi: 10.1056/nejmoa0907893
[8]
Eltawil KM, Laryea M, Peltekian K, Molinari M (2012) Rifaximin vs. conventional oral therapy for hepatic encephalopathy: a meta-analysis. World J Gastroenterol 18: 767–77. doi: 10.3748/wjg.v18.i8.767
[9]
Scarpignato C, Pelosini I (2006) Experimental and Clinical Pharmacology of Rifaximin, a Gastrointestinal Selective Antibiotic. Digestion 73: Suppl 1: 13–27. doi: 10.1159/000089776
[10]
Harputluoglu MM, Demirel U, Gul M, Temel I, Gursoy S, et al. (2012) Effects of rifaximin on bacterial translocation in thioacetamide-induced liver injury in rats. Inflammation 35: 1512–7. doi: 10.1007/s10753-012-9465-2
[11]
Zhu Q, Zou L, Jagavelu K, Simonetto DA, Huebert RC, et al. (2012) Intestinal decontamination inhibits TLR4 dependent fibronectin-mediated cross-talk between stellate cells and endothelial cells in liver fibrosis in mice. J Hepatol 56: 893–9. doi: 10.1016/j.jhep.2011.11.013
[12]
European Association for the Study of the Liver (2010) EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 53: 397–417. doi: 10.1016/j.jhep.2010.05.004
[13]
Blei AT, Córdoba J (2001) Practice Parameters Committee of the American College of Gastroenterology (2001) Hepatic Encephalopathy. Am J Gastroenterol 96: 1968–76.
[14]
Hanouneh MA, Hanouneh IA, Hashash JG, Law R, Esfeh JM, et al. (2012) The role of rifaximin in the primary prophylaxis of spontaneous bacterial peritonitis in patients with liver cirrhosis. J Clin Gastroenterol 46: 709–15. doi: 10.1097/mcg.0b013e3182506dbb
[15]
Fernández J, Acevedo J, Castro M, Garcia O, de Lope CR, et al. (2012) Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: a prospective study. Hepatology 55: 1551–61. doi: 10.1002/hep.25532
[16]
Tandon P, Delisle A, Topal JE, Garcia-Tsao G (2012) High Prevalence of Antibiotic-Resistant Bacterial Infections Among Patients With Cirrhosis at a US Liver Center. Clin Gastroenterol Hepatol 10: 1291–8. doi: 10.1016/j.cgh.2012.08.017
[17]
Pelletier G, Salmon D, Ink O, Hannoun S, Attali P, et al. (1990) Culture-negative neutrocytic ascites: a less severe variant of spontaneous bacterial peritonitis. J Hepatol 10: 327–31. doi: 10.1016/0168-8278(90)90140-m
[18]
Vlachogiannakos J, Viazis N, Vasianopoulou P, Vafiadis I, Karamanolis DG, et al. (2013) Long-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis. J Gastroenterol Hepatol 28: 450–5. doi: 10.1111/jgh.12070
DuPont HL, Jiang ZD (2004) Influence of rifaximin treatment on the susceptibility of intestinal Gram-negative flora and enterococci. Clin Microbiol Infect 10: 1009–11. doi: 10.1111/j.1469-0691.2004.00997.x
[21]
De Leo C, Eftimiadi C, Schito GC (1986) Rapid disappearance from the intestinal tract of bacteria resistant to rifaximin. Drugs Exp Clin Res 12: 979–81.
[22]
Kothary V, Scherl EJ, Bosworth B, Jiang ZD, Dupont HL, et al. (2013) Rifaximin resistance in Escherichia coli associated with inflammatory bowel disease correlates with prior rifaximin use, mutations in rpoB, and activity of PAβN-inhibitable efflux pumps. Antimicrob Agents Chemother 57: 811–7. doi: 10.1128/aac.02163-12
[23]
Valentin T, Leitner E, Rohn A, Zollner-Schwetz I, Hoenigl M, et al. (2011) Rifaximin intake leads to emergence of rifampin-resistant staphylococci. J Infect 62: 34–8. doi: 10.1016/j.jinf.2010.11.004
[24]
Gillis JC, Brogden RN (1995) Rifaximin. A review of its antibacterial activity, pharmacokinetic properties and therapeutical potential in conditions mediated by gastrointestinal bacteria. Drugs 49: 467–484. doi: 10.2165/00003495-199549030-00009
[25]
Hoover WW, Gerlach EH, Hoban DJ, Eliopoulos GM, Pfaller MA, et al. (1993) Antimicrobial activity and spectrum of rifaximin, a new topical rifamycin derivative. Diagn Microbiol Infect Dis 16: 111–8. doi: 10.1016/0732-8893(93)90004-q
[26]
Tamaskar I, Ravakhah K (2004) Spontaneous bacterial peritonitis with Pasteurella multocida in cirrhosis: case report and review of literature. South Med J 97: 1113–5. doi: 10.1097/01.smj.0000144616.66917.8a
[27]
Gustot T, Durand F, Lebrec D, Vincent JL, Moreau R (2009) Severe sepsis in cirrhosis. Hepatology 50: 2022–33. doi: 10.1002/hep.23264
[28]
Umgelter A, Reindl W, Miedaner M, Schmid RM, Huber W (2009) Failure of current antibiotic first-line regimens and mortality in hospitalized patients with spontaneous bacterial peritonitis. Infection 37: 2–8. doi: 10.1007/s15010-008-8060-9
[29]
Bajaj JS, Heuman DM, Sanyal AJ, Hylemon PB, Sterling RK, et al. (2013) Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy. PLoS One 8: e60042. doi: 10.1371/journal.pone.0060042
[30]
Rogers GB, van der Gast CJ, Bruce KD, Marsh P, Collins JE, et al. (2013) Ascitic microbiota composition is correlated with clinical severity in cirrhosis with portal hypertension. PLoS One 8: e74884. doi: 10.1371/journal.pone.0074884
[31]
Bunchorntavakul C, Chavalitdhamrong D (2012) Bacterial infections other than spontaneous bacterial peritonitis in cirrhosis. World J Hepatol 4: 158–68. doi: 10.4254/wjh.v4.i5.158
[32]
Tomás I, Diz P, Tobías A, Scully C, Donos N (2012) Periodontal health status and bacteraemia from daily oral activities: systematic review/meta-analysis. Clin Periodontol 39: 213–28. doi: 10.1111/j.1600-051x.2011.01784.x
[33]
Dewhirst FE, Chen T, Izard J, Paster BJ, Tanner AC, et al. (2010) The human oral microbiome. J Bacteriol 192: 5002–17. doi: 10.1128/jb.00542-10
[34]
Tanner A, Maiden MF, Paster BJ, Dewhirst FE (1994) The impact of 16S ribosomal RNA-based phylogeny on the taxonomy of oral bacteria. Periodontol 2000 5: 26–51. doi: 10.1111/j.1600-0757.1994.tb00017.x
[35]
Avril JL, Donnio PY, Pouedras P (1990) Selective medium for Pasteurella multocida and its use to detect oropharyngeal carriage in pig breeders. J Clin Microbiol 28: 1438–40.
[36]
Yakar T, Gü？lü M, Serin E, Ali？kan H, Husamettin E (2010) A recent evaluation of empirical cephalosporin treatment and antibiotic resistance of changing bacterial profiles in spontaneous bacterial peritonitis. Dig Dis Sci 55: 1149–54. doi: 10.1007/s10620-009-0825-1
[37]
Appenrodt B, Grünhage F, Gentemann MG, Thyssen L, Sauerbruch T, et al. (2010) Nucleotide-binding oligomerization domain containing 2 (NOD2) variants are genetic risk factors for death and spontaneous bacterial peritonitis in liver cirrhosis. Hepatology 51: 1327–33. doi: 10.1002/hep.23440
[38]
Nischalke HD, Berger C, Aldenhoff K, Thyssen L, Gentemann M, et al. (2011) Toll-like receptor (TLR) 2 promoter and intron 2 polymorphisms are associated with increased risk for spontaneous bacterial peritonitis in liver cirrhosis. J Hepatol 55: 1010–6. doi: 10.1016/j.jhep.2011.02.022
[39]
Jiang ZD, Ke S, Palazzini E, Riopel L, Dupont H (2000) In vitro activity and fecal concentration of rifaximin after oral administration. Antimicrob Agents Chemother 44: 2205–6. doi: 10.1128/aac.44.8.2205-2206.2000
